Exagen Inc. (XGN) 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 6, 2020, reports on Exagen Inc., a Delaware corporation trading on the Nasdaq Global Market. The filing references the Company's financial results for the three and nine months ended September 30, 2020, which were reported via a press release on November 10, 2020.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes and Corporate Events
- Board Resignation: Chet Burrell resigned from the Board of Directors, effective December 31, 2020.
- Reason for Departure: The resignation was not due to any disagreement with the Board or the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished regarding financial results (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2020) for actual financial performance data for the three and nine months ended September 30, 2020.
- Confirm the status of the Board of Directors following Chet Burrell's scheduled resignation on December 31, 2020.
- Verify if any new directors were appointed to fill the vacancy created by Mr. Burrell's departure.